High platelet reactivity and antiplatelet therapy resistance

Seminars in Thrombosis and Hemostasis

Volumn 38, Issue 2, 2012, Pages 200-212

  Linden, Matthew D ^a,b   Tran, Huyen ^b   Woods, Robyn ^b   Tonkin, Andrew ^b  

^a RMIT UNIVERSITY   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

antiplatelet therapy; aspirin resistance; cardiovascular disease; clopidogrel resistance; platelet hyperreactivity

Indexed keywords

ACETYLSALICYLIC ACID; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; COUMARIN DERIVATIVE; CYCLOOXYGENASE 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PRASUGREL; PROTON PUMP INHIBITOR; THROMBOXANE B2;

ACUTE CORONARY SYNDROME; ARTICLE; ATHEROGENESIS; BLEEDING; BLOOD CLOTTING PARAMETERS; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG ABSORPTION; DRUG ACETYLATION; DRUG DETERMINATION; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG MECHANISM; DRUG TREATMENT FAILURE; FATTY ACID SYNTHESIS; FLOW CYTOMETRY; GENETIC POLYMORPHISM; GENETIC SCREENING; GLYCATION; HUMAN; HYDROLYSIS; HYPERGLYCEMIA; KIDNEY FAILURE; META ANALYSIS (TOPIC); OUTCOME ASSESSMENT; OXIDATION; PATIENT COMPLIANCE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; SECONDARY PREVENTION; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOELASTOGRAPHY; THROMBOSIS; THROMBOSIS PREVENTION; URINE LEVEL;

AGED; BIOLOGICAL AVAILABILITY; BLOOD PLATELETS; CYCLOOXYGENASE 1; DIABETES COMPLICATIONS; DRUG RESISTANCE; HUMANS; PATIENT COMPLIANCE; PLATELET ACTIVATION; PLATELET AGGREGATION; TICLOPIDINE;

EID: 84858127301     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0032-1301417     Document Type: Article

References (162)

1. Lippi G, Franchini M, Targher G. Arterial thrombus formation in cardiovascular disease. Nat Rev Cardiol: 2011; 8 9 502 512
2. Rosamond W, Flegal K, Friday G., et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation: 2007; 115 5 e69 e171 (Pubitemid 46226160)
3. National Center for Health Statistics. Chartbook on Trends in the Health of Americans. Hyattsville, MD: Library of Congress Catalog Number 76-641496;2007
4. Goldschmidt PJ, Lopes N, Crawford LE, Becker RC. Atherothrombosis and coronary artery disease. In: Michelson AD. ed. Platelets. 2nd ed. San Diego: Academic Press; 2007; 629 657
5. Fitzgerald DJ, Roy L, Catella F, FitzGerald GA. Platelet activation in unstable coronary disease. N Engl J Med: 1986; 315 16 983 989 (Pubitemid 16028578)
6. Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med: 2008; 359 9 938 949
7. Cattaneo M. ADP receptor agonists. In: Michelson AD., ed. Platelets. 2nd ed. San Diego: Elsevier/Academic Press; 2006; 1124 1144
8. Lauri D, Cerletti C, de Gaetano G. Amplification of primary response of human platelets to platelet-activating factor: aspirin-sensitive and aspirin-insensitive pathways. J Lab Clin Med: 1985; 105 6 653 658 (Pubitemid 16053014)
9. Hato T, Pampori N, Shattil SJ. Complementary roles for receptor clustering and conformational change in the adhesive and signaling functions of integrin alphaIIb beta3. J Cell Biol: 1998; 141 7 1685 1695 (Pubitemid 28309181)
10. Shattil SJ, Brass LF. Induction of the fibrinogen receptor on human platelets by intracellular mediators. J Biol Chem: 1987; 262 3 992 1000 (Pubitemid 17028403)
11. Shattil SJ, Hoxie JA, Cunningham M, Brass LF. Changes in the platelet membrane glycoprotein IIb.IIIa complex during platelet activation. J Biol Chem: 1985; 260 20 11107 11114 (Pubitemid 16253272)
12. Linden MD, Jackson DE. Platelets: pleiotropic roles in atherogenesis and atherothrombosis. Int J Biochem Cell Biol: 2010; 42 11 1762 1766
13. Huo Y, Schober A, Forlow SB., et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med: 2003; 9 1 61 67 (Pubitemid 36098261)
14. Seizer P, Gawaz M, May AE. Platelet-monocyte interactionsa dangerous liaison linking thrombosis, inflammation and atherosclerosis. Curr Med Chem: 2008; 15 20 1976 1980
15. Antoniades C, Bakogiannis C, Tousoulis D, Antonopoulos AS, Stefanadis C. The CD40/CD40 ligand system: linking inflammation with atherothrombosis. J Am Coll Cardiol: 2009; 54 8 669 677
16. Smith SC Jr, Feldman TE, Hirshfeld JW Jr., et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines; ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation: 2006; 113 7 e166 e286 (Pubitemid 43879461)
17. Patrono C, Baigent C, Hirsh J, Roth G.; American College of Chest Physicians. Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest: 2008; 133 6, Suppl 199S 233S (Pubitemid 351894914)
18. Roth GJ, Stanford N, Majerus PW. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci U S A: 1975; 72 8 3073 3076
19. Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest: 1975; 56 3 624 632
20. Baigent C, Blackwell L, Collins R., et al. Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet: 2009; 373 9678 1849 1860
21. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ: 2002; 324 7329 71 86
22. Michelson AD. Antiplatelet therapies for the treatment of cardiovascular disease. Nat Rev Drug Discov: 2010; 9 2 154 169
23. Ajani UA, Ford ES, Greenland KJ, Giles WH, Mokdad AH. Aspirin use among U.S. adults: Behavioral Risk Factor Surveillance System. Am J Prev Med: 2006; 30 1 74 77 (Pubitemid 43083548)
24. U.S. Census of Population and Housing. 2010. Washington: Government Printing Office; 2011
25. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK.; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med: 2001; 345 7 494 502 (Pubitemid 32758501)
26. Mehta SR, Yusuf S, Peters RJ., et al. Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet: 2001; 358 9281 527 533 (Pubitemid 32772726)
27. Steinhubl SR, Berger PB, Mann JT III., et al. CREDO Investigators. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA: 2002; 288 19 2411 2420 (Pubitemid 35340537)
28. Chen ZM, Jiang LX, Chen YP., et al. COMMIT (Clopidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet: 2005; 366 9497 1607 1621
29. Sabatine MS, Cannon CP, Gibson CM., et al. CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med: 2005; 352 12 1179 1189 (Pubitemid 40397259)
30. Matetzky S, Shenkman B, Guetta V., et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation: 2004; 109 25 3171 3175
31. Cuisset T, Frere C, Quilici J., et al. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost: 2006; 4 3 542 549
32. Gurbel PA, Lau WC, Bliden KP, Tantry US. Clopidogrel resistance: implications for coronary stenting. Curr Pharm Des: 2006; 12 10 1261 1269 (Pubitemid 44082135)
33. Wiviott SD, Trenk D, Frelinger AL., et al. PRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation: 2007; 116 25 2923 2932 (Pubitemid 350291199)
34. Antman EM, Wiviott SD, Murphy SA., et al. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel- Thrombolysis In Myocardial Infarction) analysis. J Am Coll Cardiol: 2008; 51 21 2028 2033 (Pubitemid 351689056)
35. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol: 2003; 41 6 961 965 (Pubitemid 36315537)
36. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation: 2002; 105 14 1650 1655 (Pubitemid 34298607)
37. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin "resistanceo" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ: 2008; 336 7637 195 198 (Pubitemid 351212675)
38. Lippi G, Favaloro EJ, Salvagno GL, Franchini M. Laboratory assessment and perioperative management of patients on antiplatelet therapy: from the bench to the bedside. Clin Chim Acta: 2009; 405 1-2 8 16
39. Favaloro EJ, Lippi G, Franchini M. Contemporary platelet function testing. Clin Chem Lab Med: 2010; 48 5 579 598
40. Michelson AD, Cattaneo M, Eikelboom JW., et al. Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis; Working Group on Aspirin Resistance. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost: 2005; 3 6 1309 1311 (Pubitemid 41725257)
41. Patrono C. Aspirin resistance: definition, mechanisms and clinical read-outs. J Thromb Haemost: 2003; 1 8 1710 1713
42. Bonello L, Tantry US, Marcucci R., et al. Working Group on High On-Treatment Platelet Reactivity. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol: 2010; 56 12 919 933
43. Cattaneo M. Laboratory detection of aspirin resistance': what test should we use (if any)? Eur Heart J: 2007; 28 14 1673 1675 (Pubitemid 47227105)
44. Sweeny JM, Gorog DA, Fuster V. Antiplatelet drug resistance'. Part 1: mechanisms and clinical measurements. Nat Rev Cardiol: 2009; 6 4 273 282
45. Mattiello T, Guerriero R, Lotti LV., et al. Aspirin extrusion from human platelets through multidrug resistance protein-4-mediated transport: evidence of a reduced drug action in patients after coronary artery bypass grafting. J Am Coll Cardiol: 2011; 58 7 752 761
46. Frelinger AL, Li Y, Linden MD., et al. Aspirin resistance': role of pre-existent platelet reactivity and correlation between tests. J Thromb Haemost: 2008; 6 12 2035 2044
47. Hughes CM. Medication non-adherence in the elderly: how big is the problem? Drugs Aging: 2004; 21 12 793 811 (Pubitemid 39423335)
48. Waeber B, Leonetti G, Kolloch R, McInnes GT. Compliance with aspirin or placebo in the Hypertension Optimal Treatment (HOT) study. J Hypertens: 1999; 17 7 1041 1045 (Pubitemid 29322194)
49. Glynn RJ, Buring JE, Manson JE, LaMotte F, Hennekens CH. Adherence to aspirin in the prevention of myocardial infarction. The Physicians' Health Study. Arch Intern Med: 1994; 154 23 2649 2657
50. Dyken ML, Barnett HJ, Easton JD., et al. Low-dose aspirin and stroke. "It ain't necessarily soo" Stroke: 1992; 23 10 1395 1399
51. Kong DF. Aspirin in cardiovascular disorders. What is the optimum dose? Am J Cardiovasc Drugs: 2004; 4 3 151 158 (Pubitemid 38780001)
52. Patrono C. Prevention of myocardial infarction and stroke by aspirin: different mechanisms? Different dosage? Thromb Res: 1998; 92 1, Suppl 1 S7 S12 (Pubitemid 28480216)
53. Frelinger AL III, Li Y, Linden MD., et al. Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization. Circulation: 2009; 120 25 2586 2596
54. Patrono C, Coller B, Dalen JE., et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest: 2001; 119 1, Suppl 39S 63S (Pubitemid 32154194)
55. Taylor DW, Barnett HJ, Haynes RB., et al. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial. ASA and Carotid Endarterectomy (ACE) Trial Collaborators. Lancet: 1999; 353 9171 2179 2184 (Pubitemid 29295249)
56. The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med: 1991; 325 18 1261 1266
57. Harris WH, Athanasoulis CA, Waltman AC, Salzman EW. Prophylaxis of deep-vein thrombosis after total hip replacement. Dextran and external pneumatic compression compared with 1.2 or 0.3 gram of aspirin daily. J Bone Joint Surg Am: 1985; 67 1 57 62 (Pubitemid 15192999)
58. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest: 1982; 69 6 1366 1372 (Pubitemid 12081064)
59. Weksler BB, Pett SB, Alonso D., et al. Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients. N Engl J Med: 1983; 308 14 800 805 (Pubitemid 13114674)
60. Kurth T, Glynn RJ, Walker AM., et al. Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation: 2003; 108 10 1191 1195 (Pubitemid 37099986)
61. MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet: 2003; 361 9357 573 574 (Pubitemid 36207477)
62. Linden MD, Frelinger AL III, Przyklenk K, Furman MI, Michelson AD. Aspirin resistance: detection, mechanisms, and clinical implications. Curr Cardiol Rev: 2005; 1 3 203 211
63. Umar A, Boisseau M, Yusup A, Upur H, Bgaud B, Moore N. Interactions between aspirin and COX-2 inhibitors or NSAIDs in a rat thrombosis model. Fundam Clin Pharmacol: 2004; 18 5 559 563 (Pubitemid 39468964)
64. Lvesque LE, Brophy JM, Zhang B. The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Ann Intern Med: 2005; 142 7 481 489
65. Solomon DH, Schneeweiss S, Levin R, Avorn J. Relationship between COX-2 specific inhibitors and hypertension. Hypertension: 2004; 44 2 140 145 (Pubitemid 39014229)
66. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA: 2001; 286 8 954 959 (Pubitemid 33010342)
67. Di Minno G. Aspirin resistance and platelet turnover: a 25-year old issue. Nutr Metab Cardiovasc Dis: 2011; 21 8 542 545
68. Cambria-Kiely JA, Gandhi PJ. Aspirin resistance and genetic polymorphisms. J Thromb Thrombolysis: 2002; 14 1 51 58 (Pubitemid 36277691)
69. Censarek P, Freidel K, Udelhoven M., et al. Cyclooxygenase COX-2a, a novel COX-2 mRNA variant, in platelets from patients after coronary artery bypass grafting. Thromb Haemost: 2004; 92 5 925 928 (Pubitemid 39545513)
70. Weber AA, Zimmermann KC, Meyer-Kirchrath J, Schrör K. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet: 1999; 353 9156 900 (Pubitemid 29126885)
71. Schuster VL. Molecular mechanisms of prostaglandin transport. Annu Rev Physiol: 1998; 60 221 242 (Pubitemid 28157872)
72. Maclouf J, Folco G, Patrono C. Eicosanoids and iso-eicosanoids: constitutive, inducible and transcellular biosynthesis in vascular disease. Thromb Haemost: 1998; 79 4 691 705 (Pubitemid 28163838)
73. Frelinger AL III, Furman MI, Linden MD., et al. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation: 2006; 113 25 2888 2896 (Pubitemid 44297229)
74. Freedman JE. The aspirin resistance controversy: clinical entity or platelet heterogeneity? Circulation: 2006; 113 25 2865 2867 (Pubitemid 44297225)
75. Dav G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med: 2007; 357 24 2482 2494
76. Furman MI, Benoit SE, Barnard MR., et al. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J Am Coll Cardiol: 1998; 31 2 352 358 (Pubitemid 28153455)
77. Linden MD, Furman MI, Frelinger AL III., et al. Indices of platelet activation and the stability of coronary artery disease. J Thromb Haemost: 2007; 5 4 761 765 (Pubitemid 46563575)
78. Ajjan R, Storey RF, Grant PJ. Aspirin resistance and diabetes mellitus. Diabetologia: 2008; 51 3 385 390
79. Ferreira IA, Mocking AI, Feijge MA., et al. Platelet inhibition by insulin is absent in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol: 2006; 26 2 417 422 (Pubitemid 43732209)
80. Angiolillo DJ. Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions. Diabetes Care: 2009; 32 4 531 540
81. Akoglu H, Agbaht K, Piskinpasa S., et al. High frequency of aspirin resistance in patients with nephrotic syndrome. Nephrol Dial Transplant: 2011;; August 23 DOI: 10.1093/ndt/gfr476 [Epub ahead of print]
82. Tanrikulu AM, Ozben B, Koc M, Papila-Topal N, Ozben T, Caymaz O. Aspirin resistance in patients with chronic renal failure. J Nephrol: 2011; 24 5 636 646
83. Harrison P, Frelinger AL III, Furman MI, Michelson AD. Measuring antiplatelet drug effects in the laboratory. Thromb Res: 2007; 120 3 323 336 (Pubitemid 46879909)
84. Michelson AD, Frelinger AL III, Furman MI. Resistance to antiplatelet drugs. Eur Heart J: 2006; 8 G53 G58 (Pubitemid 44526987)
85. Catella F, FitzGerald GA. Paired analysis of urinary thromboxane B2 metabolites in humans. Thromb Res: 1987; 47 6 647 656 (Pubitemid 18032523)
86. Kazui M, Nishiya Y, Ishizuka T., et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos: 2010; 38 1 92 99
87. Lau WC, Gurbel PA, Watkins PB., et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation: 2004; 109 2 166 171 (Pubitemid 38114134)
88. Mega JL, Close SL, Wiviott SD., et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med: 2009; 360 4 354 362
89. Shuldiner AR, O'Connell JR, Bliden KP., et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA: 2009; 302 8 849 857
90. Sibbing D, Gebhard D, Koch W., et al. Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy. J Thromb Haemost: 2010; 8 8 1685 1693
91. Simon T, Verstuyft C, Mary-Krause M., et al. French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med: 2009; 360 4 363 375
92. Trenk D, Hochholzer W, Fromm MF., et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol: 2008; 51 20 1925 1934 (Pubitemid 351636443)
93. Holmes DR Jr, Dehmer GJ, Kaul S, Leifer D, O'Gara PT, Stein CM.; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; Writing Committee Members. ACCF/AHA Clopidogrel clinical alert: approaches to the FDA "boxed warningo": a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association. Circulation: 2010; 122 5 537 557
94. Mega JL, Simon T, Collet JP., et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA: 2010; 304 16 1821 1830
95. Kassimis G, Davlouros P, Xanthopoulou I, Stavrou EF, Athanassiadou A, Alexopoulos D. CYP2C19 2 and other genetic variants affecting platelet response to clopidogrel in patients undergoing percutaneous coronary intervention. Thromb Res: 2011;; DOI: 10.1016/j.thromb.2011.07.022 August 8 [Epub ahead of print]
96. Wallentin L, James S, Storey RF., et al. PLATO investigators. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet: 2010; 376 9749 1320 1328
97. Sibbing D, Byrne RA, Bernlochner I, Kastrati A. High platelet reactivity and clinical outcome - fact and fiction. Thromb Haemost: 2011; 106 2 191 202
98. Serebruany V, Cherala G, Williams C., et al. Association of platelet responsiveness with clopidogrel metabolism: role of compliance in the assessment of "resistanceo" Am Heart J: 2009; 158 6 925 932
99. Osmancik P, Jirmar R, Hulikova K., et al. A comparison of the VASP index between patients with hemodynamically complicated and uncomplicated acute myocardial infarction. Catheter Cardiovasc Interv: 2010; 75 2 158 166
100. Gurbel PA, Antonino MJ, Tantry US. Recent developments in clopidogrel pharmacology and their relation to clinical outcomes. Expert Opin Drug Metab Toxicol: 2009; 5 8 989 1004
101. Sibbing D, von Beckerath O, Schömig A, Kastrati A, von Beckerath N. Impact of body mass index on platelet aggregation after administration of a high loading dose of 600 mg of clopidogrel before percutaneous coronary intervention. Am J Cardiol: 2007; 100 2 203 205 (Pubitemid 47041981)
102. Angiolillo DJ, Fernndez-Ortiz A, Bernardo E., et al. Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted? J Invasive Cardiol: 2004; 16 4 169 174 (Pubitemid 38456448)
103. Gladding P, Webster M, Zeng I., et al. The antiplatelet effect of higher loading and maintenance dose regimens of clopidogrel: the PRINC (Plavix Response in Coronary Intervention) trial. JACC Cardiovasc Interv: 2008; 1 6 612 619
104. Patti G, Colonna G, Pasceri V, Pepe LL, Montinaro A, Di Sciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation: 2005; 111 16 2099 2106 (Pubitemid 40577905)
105. Collet JP, Hulot JS, Anzaha G., et al. CLOVIS-2 Investigators. High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2). JACC Cardiovasc Interv: 2011; 4 4 392 402
106. Sibbing D, Morath T, Stegherr J., et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost: 2009; 101 4 714 719
107. Sibbing D, Kastrati A. Risk of combining PPIs with thienopyridines: fact or fiction? Lancet: 2009; 374 9694 952 954
108. Trenk D, Hochholzer W, Frundi D., et al. Impact of cytochrome P450 3A4-metabolized statins on the antiplatelet effect of a 600-mg loading dose clopidogrel and on clinical outcome in patients undergoing elective coronary stent placement. Thromb Haemost: 2008; 99 1 174 181
109. Moceri P, Doyen D, Cerboni P, Ferrari E. Doubling the dose of clopidogrel restores the loss of antiplatelet effect induced by esomeprazole. Thromb Res: 2011; 128 5 458 462
110. Michelson AD, Linden MD, Furman MI., et al. Evidence that pre-existent variability in platelet response to ADP accounts for clopidogrel resistance'. J Thromb Haemost: 2007; 5 1 75 81 (Pubitemid 44921070)
111. Grdinic A, Vojvodic D, Djukanovic N., et al. PCI and clopidogrel: antiplatelet responsiveness and patient characteristics. Acta Cardiol: 2011; 66 3 333 340
112. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E., et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes: 2005; 54 8 2430 2435 (Pubitemid 41134272)
113. Angiolillo DJ, Badimon JJ, Saucedo JF., et al. A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial. Eur Heart J: 2011; 32 7 838 846
114. Park SH, Kim W, Park CS, Kang WY, Hwang SH, Kim W. A comparison of clopidogrel responsiveness in patients with versus without chronic renal failure. Am J Cardiol: 2009; 104 9 1292 1295
115. Camilleri E, Jacquin L, Paganelli F, Bonello L. Personalized antiplatelet therapy: review of the latest clinical evidence. Curr Cardiol Rep: 2011; 13 4 296 302
116. Breet NJ, van Werkum JW, Bouman HJ., et al. High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention. Heart: 2011; 97 12 983 990
117. Cotter G, Shemesh E, Zehavi M., et al. Lack of aspirin effect: aspirin resistance or resistance to taking aspirin? Am Heart J: 2004; 147 2 293 300 (Pubitemid 38176831)
118. Stejskal D, Vclavk J, Lacnk B, Proskov J. Aspirin resistance measured by cationic propyl gallate platelet aggregometry and recurrent cardiovascular events during 4 years of follow-up. Eur J Intern Med: 2006; 17 5 349 354 (Pubitemid 44080547)
119. Helgason CM, Bolin KM, Hoff JA., et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke: 1994; 25 12 2331 2336 (Pubitemid 24359298)
120. Mueller MR, Salat A, Stangl P., et al. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost: 1997; 78 3 1003 1007 (Pubitemid 27417291)
121. Poston RS, Gu J, Brown JM., et al. Endothelial injury and acquired aspirin resistance as promoters of regional thrombin formation and early vein graft failure after coronary artery bypass grafting. J Thorac Cardiovasc Surg: 2006; 131 1 122 130 (Pubitemid 43049792)
122. Berrouschot J, Schwetlick B, von Twickel G., et al. Aspirin resistance in secondary stroke prevention. Acta Neurol Scand: 2006; 113 1 31 35
123. Zhang Y, Liang J, Zhou YJ, Yuan H, Zhang YZ, Dong L. [Study on the relationship between aspirin resistance and incidence of myonecrosis after non-emergent percutaneous coronary intervention]. Zhonghua Xin Xue Guan Bing Za Zhi: 2005; 33 8 695 699
124. Borna C, Lazarowski E, van Heusden C, Ohlin H, Erlinge D. Resistance to aspirin is increased by ST-elevation myocardial infarction and correlates with adenosine diphosphate levels. Thromb J: 2005; 3 10
125. Grundmann K, Jaschonek K, Kleine B, Dichgans J, Topka H. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol: 2003; 250 1 63 66 (Pubitemid 36206686)
126. Hobikoglu GF, Norgaz T, Aksu H., et al. High frequency of aspirin resistance in patients with acute coronary syndrome. Tohoku J Exp Med: 2005; 207 1 59 64 (Pubitemid 41195359)
127. McCabe DJ, Harrison P, Mackie IJ., et al. Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA. Platelets: 2005; 16 5 269 280 (Pubitemid 40943921)
128. Yilmaz MB, Balbay Y, Caldir V., et al. Late saphenous vein graft occlusion in patients with coronary bypass: possible role of aspirin resistance. Thromb Res: 2005; 115 1-2 25 29 (Pubitemid 39572751)
129. Pamukcu B, Oflaz H, Onur I., et al. Aspirin-resistant platelet aggregation in a cohort of patients with coronary heart disease. Blood Coagul Fibrinolysis: 2007; 18 5 461 465 (Pubitemid 46975949)
130. Macchi L, Christiaens L, Brabant S., et al. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res: 2002; 107 1-2 45 49 (Pubitemid 35284424)
131. Andersen K, Hurlen M, Arnesen H, Seljeflot I. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res: 2002; 108 1 37 42 (Pubitemid 36197660)
132. Golaski J, Nocu M, Rzalski M, Drygas W, Wataa C. An in vitro model for the detection of reduced platelet sensitivity to acetylsalicylic acid. Blood Coagul Fibrinolysis: 2004; 15 2 187 195 (Pubitemid 38392372)
133. Buchanan MR, Schwartz L, Bourassa M, Brister SJ, Peniston CM.; BRAT Investigators. Results of the BRAT studya pilot study investigating the possible significance of ASA nonresponsiveness on the benefits and risks of ASA on thrombosis in patients undergoing coronary artery bypass surgery. Can J Cardiol: 2000; 16 11 1385 1390 (Pubitemid 32094223)
134. Gurbel PA, Bliden KP. A new method of representing drug-induced platelet inhibition: better description of time course, response variability, non-response, and heightened activity. Platelets: 2003; 14 7-8 481 483 (Pubitemid 38096119)
135. Tantry US, Bliden KP, Gurbel PA. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol: 2005; 46 9 1705 1709 (Pubitemid 41531626)
136. Chen WH, Lee PY, Ng W., et al. Relation of aspirin resistance to coronary flow reserve in patients undergoing elective percutaneous coronary intervention. Am J Cardiol: 2005; 96 6 760 763 (Pubitemid 41317643)
137. Chen WH, Lee PY, Ng W, Tse HF, Lau CP. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol: 2004; 43 6 1122 1126 (Pubitemid 38353000)
138. Wang JC, Aucoin-Barry D, Manuelian D., et al. Incidence of aspirin nonresponsiveness using the Ultegra Rapid Platelet Function Assay-ASA. Am J Cardiol: 2003; 92 12 1492 1494 (Pubitemid 37532584)
139. Breet NJ, van Werkum JW, Bouman HJ., et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA: 2010; 303 8 754 762
140. Buonamici P, Marcucci R, Migliorini A., et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol: 2007; 49 24 2312 2317 (Pubitemid 46891710)
141. Cuisset T, Cayla G, Frere C., et al. Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment? EuroIntervention: 2009; 5 3 325 329
142. Frere C, Cuisset T, Quilici J., et al. ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. Thromb Haemost: 2007; 98 4 838 843 (Pubitemid 47555077)
143. Geisler T, Zürn C, Simonenko R., et al. Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions. Eur Heart J: 2010; 31 1 59 66
144. Geisler T, Langer H, Wydymus M., et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J: 2006; 27 20 2420 2425 (Pubitemid 44522148)
145. Gori AM, Marcucci R, Migliorini A., et al. Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents. J Am Coll Cardiol: 2008; 52 9 734 739
146. Gurbel PA, Antonino MJ, Bliden KP., et al. Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target. Platelets: 2008; 19 8 595 604
147. Gurbel PA, Bliden KP, Guyer K., et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J Am Coll Cardiol: 2005; 46 10 1820 1826 (Pubitemid 41579802)
148. Gurbel PA, Bliden KP, Samara W., et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol: 2005; 46 10 1827 1832 (Pubitemid 41579803)
149. Hochholzer W, Trenk D, Bestehorn HP., et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol: 2006; 48 9 1742 1750 (Pubitemid 44648629)
150. Bliden KP, DiChiara J, Tantry US, Bassi AK, Chaganti SK, Gurbel PA. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? J Am Coll Cardiol: 2007; 49 6 657 666 (Pubitemid 46205039)
151. Lev EI, Patel RT, Maresh KJ., et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol: 2006; 47 1 27 33 (Pubitemid 43005160)
152. Cuisset T, Frere C, Quilici J., et al. High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes. Thromb Haemost: 2007; 97 2 282 287 (Pubitemid 46592149)
153. Barragan P, Bouvier JL, Roquebert PO., et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv: 2003; 59 3 295 302 (Pubitemid 36792384)
154. Blindt R, Stellbrink K, De Taeye A., et al. The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis. Thromb Haemost: 2007; 98 6 1329 1334 (Pubitemid 350239106)
155. Bonello L, Paganelli F, Arpin-Bornet M., et al. Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J Thromb Haemost: 2007; 5 8 1630 1636 (Pubitemid 47091403)
156. Linnemann B, Schwonberg J, Rechner AR, Mani H, Lindhoff-Last E. Assessment of clopidogrel non-response by the PFA-100 system using the new test cartridge INNOVANCE PFA P2Y. Ann Hematol: 2010; 89 6 597 605
157. McGlasson DL, Shah AD, Fritsma GA. Ability of the INNOVANCE PFA P2Y system to detect clopidogrel-induced ADP receptor blockade in preangiocath individuals. Blood Coagul Fibrinolysis: 2011; 22 7 583 587
158. Marcucci R, Gori AM, Paniccia R., et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation: 2009; 119 2 237 242
159. Migliorini A, Valenti R, Marcucci R., et al. High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease. Circulation: 2009; 120 22 2214 2221
160. Patti G, Nusca A, Mangiacapra F, Gatto L, D'Ambrosio A, Di Sciascio G. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. J Am Coll Cardiol: 2008; 52 14 1128 1133
161. Price MJ, Endemann S, Gollapudi RR., et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J: 2008; 29 8 992 1000 (Pubitemid 351844676)
162. Valgimigli M, Campo G, de Cesare N., et al. Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel (3T/2R) Investigators. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study. Circulation: 2009; 119 25 3215 3222